{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:12:59Z","timestamp":1793812379183,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41409-024-02385-1","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:08:04Z","timestamp":1722470884000},"page":"1440-1448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma"],"prefix":"10.1038","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-9260","authenticated-orcid":false,"given":"Zachary M.","family":"Avigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Arinsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fausel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7873-1597","authenticated-orcid":false,"given":"Joseph","family":"Bubalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Milkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"2385_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94.","journal-title":"Blood Cancer J"},{"key":"2385_CR2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","volume":"14","author":"I Pusic","year":"2008","unstructured":"Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transpl. 2008;14:1045\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2385_CR3","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/sj.bmt.1702066","volume":"24","author":"JA P\u00e9rez-Sim\u00f3n","year":"1999","unstructured":"P\u00e9rez-Sim\u00f3n JA, Mart\u00edn A, Caballero D, Corral M, Nieto MJ, Gonzalez M, et al. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transpl. 1999;24:1279\u201383.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transpl. 2014;20:295\u2013308.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2385_CR5","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/leu.2009.127","volume":"23","author":"S Giralt","year":"2009","unstructured":"Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23:1904\u201312.","journal-title":"Leukemia"},{"key":"2385_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/bmt.2008.410","volume":"43","author":"W Bensinger","year":"2009","unstructured":"Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transpl. 2009;43:181\u201395.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.bmt.1700867","volume":"20","author":"A Alegre","year":"1997","unstructured":"Alegre A, Tom\u00e1s JF, Mart\u00ednez-Chamorro C, Gil-Fern\u00e1ndez JJ, Fern\u00e1ndez-Villalta MJ, Arranz R, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transpl. 1997;20:211\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jca.21360","volume":"30","author":"SA Tuchman","year":"2015","unstructured":"Tuchman SA, Bacon WA, Huang LW, Long G, Rizzieri D, Horwitz M, et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J Clin Apher. 2015;30:176\u201382.","journal-title":"J Clin Apher"},{"key":"2385_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/bmt.2008.369","volume":"43","author":"MA Gertz","year":"2009","unstructured":"Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transpl. 2009;43:619\u201325.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR10","doi-asserted-by":"publisher","first-page":"770.e1","DOI":"10.1016\/j.jtct.2021.06.016","volume":"27","author":"I Vaxman","year":"2021","unstructured":"Vaxman I, Muchtar E, Jacob E, Kapoor P, Kumar S, Dispenzieri A, et al. The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transpl Cell Ther. 2021;27:770.e1\u2013.e7.","journal-title":"Transpl Cell Ther"},{"key":"2385_CR11","doi-asserted-by":"publisher","first-page":"590.e1","DOI":"10.1016\/j.jtct.2021.04.016","volume":"27","author":"A Johnsrud","year":"2021","unstructured":"Johnsrud A, Ladha A, Muffly L, Shiraz P, Goldstein G, Osgood V, et al. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +\/- Plerixafor versus Granulocyte Colony-Stimulating Factor +\/- Plerixafor in the Lenalidomide Era. Transpl Cell Ther. 2021;27:590.e1\u2013.e8.","journal-title":"Transpl Cell Ther"},{"key":"2385_CR12","doi-asserted-by":"publisher","first-page":"244.e1","DOI":"10.1016\/j.jtct.2020.12.009","volume":"27","author":"BA Zannetti","year":"2021","unstructured":"Zannetti BA, Saraceni F, Cellini C, Fabbri E, Monaco F, Guarini A, et al. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study. Transpl Cell Ther. 2021;27:244.e1\u2013.e8.","journal-title":"Transpl Cell Ther"},{"key":"2385_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3816\/CLM.2006.n.014","volume":"6","author":"D Dingli","year":"2006","unstructured":"Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, Litzow MR, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma. 2006;6:384\u20138.","journal-title":"Clin Lymphoma Myeloma"},{"key":"2385_CR14","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/bmt.2015.190","volume":"50","author":"GL Uy","year":"2015","unstructured":"Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, et al. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transpl. 2015;50:1513\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MOH.0b013e328338b7d5","volume":"17","author":"I Pusic","year":"2010","unstructured":"Pusic I, DiPersio JF. Update on clinical experience with AMD3100, an SDF-1\/CXCL12\u2013CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol. 2010;17:319\u201326.","journal-title":"Curr Opin Hematol"},{"key":"2385_CR16","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1182\/blood-2005-02-0468","volume":"106","author":"N Flomenberg","year":"2005","unstructured":"Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106:1867\u201374.","journal-title":"Blood"},{"key":"2385_CR17","first-page":"475","volume":"50","author":"M Bittrich","year":"2023","unstructured":"Bittrich M, Kriegsmann K, Tietze-Stolley C, Movassaghi K, Grube M, Vucinic V, et al. A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation. Transfus Med Hemother. 2023;50:475\u201390.","journal-title":"Transfus Med Hemother"},{"key":"2385_CR18","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","volume":"113","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720\u20136.","journal-title":"Blood"},{"key":"2385_CR19","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1111\/j.1537-2995.2011.03136.x","volume":"51","author":"J Li","year":"2011","unstructured":"Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, et al. Effectiveness and cost analysis of \u201cjust-in-time\u201d salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion. 2011;51:2175\u201382.","journal-title":"Transfusion"},{"key":"2385_CR20","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/bmt.2015.322","volume":"51","author":"S Afifi","year":"2016","unstructured":"Afifi S, Adel NG, Devlin S, Duck E, Vanak J, Landau H, et al. Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transpl. 2016;51:546\u201352.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR21","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/bmt.2013.52","volume":"48","author":"F Awan","year":"2013","unstructured":"Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, et al. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transpl. 2013;48:1279\u201384.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR22","first-page":"328","volume":"22","author":"A Zappaterra","year":"2024","unstructured":"Zappaterra A, Civettini I, Cafro AM, Pezzetti L, Pierini S, Anghilieri M, et al. Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients. Blood Transfus. 2024;22:328\u201337.","journal-title":"Blood Transfus"},{"key":"2385_CR23","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1080\/10428194.2023.2253479","volume":"64","author":"E Eleutherakis Papaiakovou","year":"2023","unstructured":"Eleutherakis Papaiakovou E, Terpos E, Kanellias N, Migkou M, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation. Leuk Lymphoma. 2023;64:2140\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2385_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11507-9","volume":"23","author":"J Kauer","year":"2023","unstructured":"Kauer J, Freundt EP, Schmitt A, Weinhold N, Mai EK, M\u00fcller-Tidow C, et al. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials. BMC Cancer. 2023;23:1132.","journal-title":"BMC Cancer"},{"key":"2385_CR25","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009;114:1729\u201335.","journal-title":"Blood"},{"key":"2385_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.bbmt.2008.04.008","volume":"14","author":"T Mark","year":"2008","unstructured":"Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transpl. 2008;14:795\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2385_CR27","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"2385_CR28","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.V91.9.3148","volume":"91","author":"N Ketterer","year":"1998","unstructured":"Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood. 1998;91:3148\u201355.","journal-title":"Blood"},{"key":"2385_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/sj.bmt.1702008","volume":"24","author":"G Benedetti","year":"1999","unstructured":"Benedetti G, Patoia L, Giglietti A, Alessio M, Pelicci P, Grignani F. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients. Bone Marrow Transpl. 1999;24:971\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/sj.bmt.1704826","volume":"35","author":"B Oran","year":"2005","unstructured":"Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, et al. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transpl. 2005;35:567\u201375.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR31","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/sj.bmt.1701800","volume":"23","author":"DA Stewart","year":"1999","unstructured":"Stewart DA, Guo D, Luider J, Auer I, Klassen J, Ching E, et al. Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose. Bone Marrow Transplant. 1999;23:1237\u201343.","journal-title":"Bone Marrow Transplant"},{"key":"2385_CR32","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.bbmt.2010.11.021","volume":"17","author":"PJ Stiff","year":"2011","unstructured":"Stiff PJ, Micallef I, Nademanee AP, Stadtmauer EA, Maziarz RT, Bolwell BJ, et al. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transpl. 2011;17:1146\u201353.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2385_CR33","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.1200\/jco.2014.32.15_suppl.7046","volume":"32","author":"MA Fiala","year":"2014","unstructured":"Fiala MA, Bhamidipati PK, Wang S, Sturgill T, Gao F, Abboud CN, et al. The impact of CD34+ cell dose and comorbidities on engraftment following autologous hematopoietic stem cell transplantation (ASCT). J Clin Oncol. 2014;32:7046.","journal-title":"J Clin Oncol"},{"key":"2385_CR34","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.1998.16.4.1547","volume":"16","author":"KR Desikan","year":"1998","unstructured":"Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol. 1998;16:1547\u201353.","journal-title":"J Clin Oncol"},{"key":"2385_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.bmt.1702879","volume":"27","author":"O Fitoussi","year":"2001","unstructured":"Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, Pigneux A, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transpl. 2001;27:837\u201342.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/sj.bmt.1703840","volume":"31","author":"E Jantunen","year":"2003","unstructured":"Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlam\u00e4ki E, Remes K. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transpl. 2003;31:347\u201351.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/jca.21280","volume":"28","author":"L Chaudhary","year":"2013","unstructured":"Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, et al. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. J Clin Apher. 2013;28:359\u201367.","journal-title":"J Clin Apher"},{"key":"2385_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/bmt.2010.78","volume":"46","author":"LJ Costa","year":"2011","unstructured":"Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transpl. 2011;46:64\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/bmt.2011.133","volume":"47","author":"S Abhyankar","year":"2012","unstructured":"Abhyankar S, DeJarnette S, Aljitawi O, Ganguly S, Merkel D, McGuirk J. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transpl. 2012;47:483\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2385_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbmt.2012.08.010","volume":"19","author":"IN Micallef","year":"2013","unstructured":"Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transpl. 2013;19:87\u201393.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2385_CR41","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jcyt.2015.09.002","volume":"17","author":"L Veltri","year":"2015","unstructured":"Veltri L, Cumpston A, Shillingburg A, Wen S, Luo J, Leadmon S, et al. Hematopoietic progenitor cell mobilization with \u201cjust-in-time\u201d plerixafor approach is a cost-effective alternative to routine plerixafor use. Cytotherapy. 2015;17:1785\u201392.","journal-title":"Cytotherapy"},{"key":"2385_CR42","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3324\/haematol.2022.282269","volume":"108","author":"B Dhakal","year":"2023","unstructured":"Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, et al. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. 2023;108:2249\u201354.","journal-title":"Haematologica"},{"key":"2385_CR43","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.bbmt.2010.08.018","volume":"17","author":"P Shaughnessy","year":"2011","unstructured":"Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transpl. 2011;17:729\u201336.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2385_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1537-2995.2011.03206.x","volume":"52","author":"P Vishnu","year":"2012","unstructured":"Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion. 2012;52:55\u201362.","journal-title":"Transfusion"},{"key":"2385_CR45","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1182\/blood.V118.21.4059.4059","volume":"118","author":"NG Adel","year":"2011","unstructured":"Adel NG, Duck E, Collum K, McCullagh E, Reich L, Landau H, et al. Cost Analysis of Using Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients Treated At Memorial Sloan-Kettering Cancer Center (MSKCC). Blood. 2011;118:4059.","journal-title":"Blood"},{"key":"2385_CR46","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1016\/j.bbmt.2009.12.160","volume":"16","author":"CJ Campen","year":"2010","unstructured":"Campen CJ, Armstrong EP, Christian JA, Hadeed S, Yeager AM. Comparative Cost-Effectiveness Of Plerixafor Plus Granulocyte-Colony Stimulating Factor Versus Cyclophosphamide Plus Granulocyte-Colony Stimulating For Autologous Peripheral Blood Stem Cell Mobilization In Patients With Non-Hodgkin\u2019s Lymphoma. Biol Blood Marrow Transplant. 2010;16:S206.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2385_CR47","unstructured":"Plerixafor. Lexi-Drugs online: UpToDate Inc.; 2024 https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/1312540."}],"updated-by":[{"DOI":"10.1038\/s41409-024-02442-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02385-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02385-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02385-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T07:03:13Z","timestamp":1729321393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02385-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2385"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02385-1","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41409-024-02442-9","asserted-by":"object"}]},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41409-024-02442-9","URL":"https:\/\/doi.org\/10.1038\/s41409-024-02442-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DP: honoraria from Sanofi. TM: Employment at Karyopharm Therapeutics. AC: consulting for Sanofi. JR: consulting and honoraria from Sanofi. ZMA, SA, CF, JB, EM, WF and GM have no relevant conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Patient data was retrospectively collected and reviewed in accordance with Declaration of Helsinki. This research protocol was approved by each transplant center\u2019s Institutional Review Board, with the final study approved by the Institutional Review Board of the Mount Sinai School of Medicine (STUDY-19-00411-MOD002).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}